Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825173 | Clinical Therapeutics | 2015 | 28 Pages |
Abstract
Spironolactone could be added to preexisting AD/RP/AHT therapy in patients with DN to prevent or slow DN progression by reducing proteinuria. The addition of spironolactone would likely provide even more beneficial effect in patients with DN and hypertension due to the BP reduction associated with spironolactone use. However, the beneficial effects of spironolactone add-on should be weighed against its potential risks, especially hyperkalemia. The long-term effects of spironolactone add-on on renal outcomes and mortality need to be studied.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jing MS, Weiquan MS, Ling MS, Xiangqiong MS, Ailing MS,